Science Corp. Posts 36-Month PRIMA BCI Follow-Up in Geographic Atrophy

Science Corp. has released 36-month follow-up results from the PRIMA clinical trial, reporting what the company describes as durable vision restoration in legally blind patients with geographic atrophy, the advanced atrophic stage of dry age-related macular degeneration. The brief Business Wire announcement marks the longest disclosed follow-up window for the PRIMA brain-computer interface to date.

What the announcement states

The press release identifies four anchored facts:

• Device classification: PRIMA, described by the company as a brain-computer interface
• Follow-up duration: 36 months
• Indication: Geographic atrophy
• Reported outcome: Vision restoration in blind patients, termed "durable"

The release carries no acuity figures, no patient-count breakdown, and no adverse-event tally. Clinical outcomes such as ETDRS letter gains, reading-speed metrics, and implant-retention rates remain unreported.

Why this cohort matters

Geographic atrophy involves progressive loss of photoreceptors, retinal pigment epithelium, and choriocapillaris within the macula. Standard functional testing for the disease relies on pattern electroretinography, microperimetry, and low-luminance reading assessments rather than scalp EEG. The lesion typically spares peripheral vision while producing dense central scotomas, leaving patients legally blind by visual-acuity and visual-field criteria even when navigational vision persists.

How the BCI label applies

Readers should note that the company's use of "brain-computer interface" refers to a retinal-stimulating subretinal prosthesis that bypasses degenerated outer retinal layers, not a scalp-EEG or intracranial recording array. The prosthesis converts incident light into stimulation patterns delivered to surviving inner retinal neurons, producing a phosphene-based visual percept. This distinguishes PRIMA from motor or speech BCIs that record cortical activity.

What neurophysiology labs would need to operationalize

If the PRIMA system moves into routine clinical use, ophthalmic electrophysiology services will face a new testing population:

• Post-implant pattern ERG protocols will require stimulus conditions that distinguish residual native outer-retinal responses from prosthetic output.
• Full-field flash ERG at low luminance may help monitor implant integrity over time.
• Multifocal ERG testing near the prosthesis edge will need updated normative ranges, since surgical placement alters local outer-retinal architecture.
• Reading-speed and low-luminance visual-function testing — not standard EEG work — will provide the patient-centered efficacy endpoints clinicians want for return visits.

Open data points

The 36-month milestone signals device durability rather than efficacy magnitude. Clinical neurophysiologists and retinal specialists will look for several unreported variables before changing practice:

• Mean ETDRS letter change from baseline
• Proportion of patients gaining at least 15 letters
• Device-explant rate at three years
• Incidence of serious ocular adverse events through year three
• Performance in patients with bilateral versus unilateral implants

The press release also leaves regulatory positioning unspecified. The company has not stated whether the data support a premarket approval submission, an FDA De Novo request, or an update to CE Mark documentation under the existing European clinical program.

What comes next

Full publication of the 36-month dataset, expected in a peer-reviewed ophthalmology or visual-neuroscience journal, will let independent groups verify the acuity gains, lesion-progression data, and adverse-event profile. Referral centers already implanting subretinal prostheses should expect updated enrollment protocols within the coming quarter if Science Corp.'s disclosure timeline holds. Until those figures appear in print, the announcement registers as a durability milestone rather than a practice-changing effectiveness endpoint.